STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.66 CNY | -1.74% |
|
-4.23% | -44.29% |
Staidson Beijing BioPharmaceuticals Co Ltd is a China-based company mainly engaged in the research and development (R&A), production and marketing of biological drugs. The drugs developed, produced and sold by the Company mainly include protein drugs, chemical drugs and other categories, and the treatment areas focus on infectious diseases, autoimmune diseases and nervous system diseases. The Company's R&D pipeline products include BDB-001, STSA-1002, STSA-1005, STSA-1002, STSA-1005, STSA-1201, STSA-1301, STSP-0601, STSG-0002, and others. The Company's marketed products are mainly innovative biological drugs Sutepsen and special varieties Shutaiqing and its series of products.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -44.29% | 372M | |
| +2.99% | 95.18B | |
| -4.34% | 37.55B | |
| +75.79% | 28.2B | |
| -14.61% | 15.63B | |
| -3.46% | 13.63B | |
| -12.31% | 11.5B | |
| +184.77% | 10.81B | |
| -54.13% | 9.23B | |
| +6.22% | 9.09B |
- Stock Market
- Equities
- 300204 Stock
- News Staidson (Beijing) BioPharmaceuticals Co., Ltd.
- Staidson Pharma Unit Gets FDA's Emergency Use Authorization for COVID-19 Drug; Shares Soar 18%
